Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Letters to the editor

Fidan Yousuf and Tim Cross
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.14-3-323
Clin Med June 2014
Fidan Yousuf
ARoyal Liverpool Hospital, Royal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool, UK
Roles: ST6 in hepatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Cross
BRoyal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool, UK
Roles: Consultant hepatologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Non-selective β-adrenoceptor blockers in patients with decompensated liver disease

Editor – We read with great interest the excellent article ‘Drug therapies in liver disease’ by Collins et al (Clin Med December 2013 pp 585–91). However, the section regarding the use of β-blockers warrants further comment.

Although the use of non-selective β-adrenoceptor blockers is strongly supported in the use of primary and secondary prophylaxis of variceal bleeding,1 there has been some controversy with its use in patients with advanced cirrhosis. In a study by Serste et al,2 151 patients with Child Pugh C cirrhosis and refractory ascites were assessed. Seventy-seven patients were being treated with β-blockers and 74 were not. At 1 year, 19% of patients treated with β-blockers were alive, compared to 64% who were not (p < 0.0001). A follow-up study by the same group found that inpatients with refractory ascites and on β-blockers had a higher risk of paracentesis-induced circulatory dysfunction.

Admittedly the studies have flaws and robust randomised controlled trials are needed, but clinicians should be cautious when using these drugs in patients with advanced liver disease.

Footnotes

  • Please submit letters for the editor's consideration within three weeks of receipt of Clinical Medicine. Letters should ideally be limited to 350 words, and sent by email to: clinicalmedicine{at}rcplondon.ac.uk

  • © 2014 Royal College of Physicians

References

  1. ↵
    1. Tripathi D,
    2. Hayes PC
    . Beta-blockers in portal hypertension: new developments and controversies. Liver Int 2013;doi: 10.1111/liv.12360 [Epub ahead of print].
  2. ↵
    1. Sersté T,
    2. Melot C,
    3. Francoz C,
    4. et al.
    Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017–22.doi:10.1002/hep.23775
    OpenUrlCrossRefPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Letters to the editor
Fidan Yousuf, Tim Cross
Clinical Medicine Jun 2014, 14 (3) 323; DOI: 10.7861/clinmedicine.14-3-323

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Letters to the editor
Fidan Yousuf, Tim Cross
Clinical Medicine Jun 2014, 14 (3) 323; DOI: 10.7861/clinmedicine.14-3-323
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Non-selective β-adrenoceptor blockers in patients with decompensated liver disease
    • Footnotes
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Response
  • Functional disorders and chronic pain
  • A further explanation for chest pain without visible coronary artery disease
Show more Letters to the editor

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians